{"filing":{"accession_number":"0001437749-26-019653","cik":"0000925741","ticker":"BCDA","company_name":"BioCardia, Inc.","form":"8-K","filing_date":"2026-06-05","report_date":null,"primary_document":"bcda20260605d_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/925741/000143774926019653/bcda20260605d_8k.htm"},"events":[{"id":3662,"run_id":3212,"accession_number":"0001437749-26-019653","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"BioCardia disclosed receipt of FDA meeting minutes confirming that its ongoing CardiAMP Heart Failure II Trial may support Premarket Approval (PMA) for the CardiAMP Cell Therapy System. This is a material regulatory milestone for a clinical-stage biotech company, as FDA confirmation of trial adequacy for PMA is a significant de-risking event that would affect investor assessment of the company's path to commercialization. However, this does not fit neatly into the standard taxonomy categories (not an earnings release, executive change, M\u0026A, impairment, or other enumerated events), warranting classification as other_material.","company_name":"BioCardia, Inc.","ticker":"BCDA","filing_date":"2026-06-05","items":[{"id":4659,"accession_number":"0001437749-26-019653","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"BioCardia disclosed receipt of FDA meeting minutes confirming that its ongoing CardiAMP Heart Failure II Trial may support Premarket Approval (PMA) for the CardiAMP Cell Therapy System. This is a material regulatory milestone for a clinical-stage biotech company, as FDA confirmation of trial adequacy for PMA is a significant de-risking event that would affect investor assessment of the company's path to commercialization. However, this does not fit neatly into the standard taxonomy categories (not an earnings release, executive change, M\u0026A, impairment, or other enumerated events), warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T16:49:42.477797+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4659,"accession_number":"0001437749-26-019653","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"BioCardia disclosed receipt of FDA meeting minutes confirming that its ongoing CardiAMP Heart Failure II Trial may support Premarket Approval (PMA) for the CardiAMP Cell Therapy System. This is a material regulatory milestone for a clinical-stage biotech company, as FDA confirmation of trial adequacy for PMA is a significant de-risking event that would affect investor assessment of the company's path to commercialization. However, this does not fit neatly into the standard taxonomy categories (not an earnings release, executive change, M\u0026A, impairment, or other enumerated events), warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T16:49:42.477797+00:00","company_name":"BioCardia, Inc.","ticker":"BCDA","filing_date":"2026-06-05"}]}